Stocks · News reference
Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $250 to $260.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-10-06 AccNo: 0000947871-26-000922 Size: 186 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
The global paternity and relationship testing market is expanding beyond traditional paternity testing into broader applications including maternity, grandparent, sibling, and infidelity testing. The market is projected to grow from $1.08 billion in 2025 to $1.45 billion by 2030 at a CAGR of 6.1%. Growth is driven by increased direct-to-consumer genetic testing accessibility, cultural shifts in family definitions, and demand for legally recognized testing. However, the market faces challenges from increased competition, lower pricing, and regulatory complexity across jurisdictions.
Quest Diagnostics (DGX) is experiencing growth across physician, hospital, and consumer channels, driven by customer wins and an expanding advanced diagnostics portfolio delivering double-digit growth. The company targets 3% annual cost savings through AI and automation initiatives. However, reimbursement uncertainty, cost pressures, and elevated debt of $5.63 billion remain concerns that could impact margins and financial flexibility.